{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"2"}]}],"title":"Decline >=50% from baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"1"}]}],"title":"Decline >=90% from baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"731"},{"groupId":"OG001","value":"330"}],"units":"Participants"}],"description":"Participants were evaluable for PSA response rate if they had a PSA level measured at baseline and at least 1 post-baseline assessment. Both PSA responses of \\> 50% and \\> 90% were determined. PSA responses required confirmation with a subsequent assessment that was conducted at least 3 weeks later.","groups":[{"description":"In DB Phase, participants received Enzalutamide capsules 160 mg orally per day. Participants who completed DB Phase, entered in optional OLE Phase and received same treatment until unacceptable toxicity, confirmed disease progression and the participant was scheduled to initiate a new systemic anti-neoplastic therapy, death or withdrawal (median treatment duration was 8.3 months).","id":"OG000","title":"Enzalutamide"},{"description":"In DB Phase, participants received placebo capsules (for Enzalutamide) orally per day. Participants who completed DB Phase, entered in optional OLE Phase and received Enzalutamide capsules 160 mg orally per day until unacceptable toxicity, confirmed disease progression and the participant was scheduled to initiate a new systemic anti-neoplastic therapy, death or withdrawal (median treatment duration was 3.0 months in DB Phase and 7.7 months in OLE Phase).","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Evaluable ITT population included participants who were part of the ITT Population and had a PSA level measured at baseline and at least 1 post-baseline assessment.","reportingStatus":"POSTED","timeFrame":"During DB phase (up to 24 months)","title":"Percentage of Participants With Prostate Specific Antigen (PSA) Response","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}